Study of ORIC-101 in Combination With Anticancer Therapy

NCT03928314 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

83

Enrollment

INDUSTRY

Sponsor class

Stopped IND Withdrawn

Conditions

Solid Tumor

Interventions

DRUG: ORIC-101
DRUG: Nab-paclitaxel

Sponsor

ORIC Pharmaceuticals